Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Jaime E Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Shirin Khambata-Ford, Shawn Rivera, Jelveh Lameh, Ekaterina Rudenko, Jordan Thornes, Sarah Todt, Jason Gerhold, Ying Huang, Jeffrey E Miller, Alexander Perl, Mark J. Levis, Kazumi Ito

Blood (2023) 142 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2023-186658

Published: 2023

Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Blood (2023) 142 (Supplement 1): 832.

https://doi.org/10.1182/blood-2023-186785

Published: 2023

Journal Articles

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Pau Montesinos, Alexander Perl, Mikkael A. Sekeres, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Richard F Schlenk, Harry P. Erba, Hervé Dombret

Blood (2023) 142 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2023-187286

Published: 2023

Journal Articles

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Blood (2023) 142 (Supplement 1): 1532.

https://doi.org/10.1182/blood-2023-181792

Published: 2023

Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk

Blood (2023) 142 (Supplement 1): 972.

https://doi.org/10.1182/blood-2023-186206

Published: 2023

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Blood (2022) 140 (Supplement 1): 2130–2132.

https://doi.org/10.1182/blood-2022-169011

Published: 2022

Journal Articles

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Blood (2022) 140 (Supplement 1): 546–548.

https://doi.org/10.1182/blood-2022-162739

Published: 2022

Journal Articles

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris V Afanasyev, Professor, Sebastian Grosicki, MD PhD, Raymond SM Wong, MD, Achilles Anagnostopoulos, MD, Benjamin Brenner, MD, Claudio Denzlinger, MD, Giuseppe Rossi, MD, Arnon Nagler, MD MSc, Ana Isabel Rosell Mas, PhD, Frank Mannino, PhD, Nicole L. Stone, PhD, Geoffrey Chan, MD, Yasser Mostafa Kamel, MD MSc, MBA, Dominik L.D. Selleslag, MD

Blood (2015) 126 (23): 1661.

https://doi.org/10.1182/blood.V126.23.1661.1661

Published: 2015

Journal Articles

Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy

Blood (2013) 122 (21): 5214.

https://doi.org/10.1182/blood.V122.21.5214.5214

Published: 2013

Journal Articles

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Moshe Mittelman, MD, Sarit Assouline, Evangelos Briasoulis, Arancha Alonso, MD, Regina Garcia Delgado, MD, Peter O'Gorman, M.D., Hyeoung Joon Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Andrey Zaritskey, Catherine M. Flynn, MD, MRCP, FRCPath, Yoo-Hong Min, María Diez-Campelo, Alexandr Myasnikov, Frank Mannino, Yasser Mostafa Kamel, Conrad Messam, Nicole L. Stone, PhD, Geoffrey W. Chan, MD

Blood (2012) 120 (21): 3822.

https://doi.org/10.1182/blood.V120.21.3822.3822

Published: 2012

Journal Articles

Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia

Geoffrey Dusheiko, MD, Nezam H Afdhal, MD, Edoardo Giannini, Pei-Jer Chen, Kwang-Hyub Han, Yasser Mostafa Kamel, Andres Brainsky, MD, James Geib, Sandra Y. Vasey, MS, Rita Patwardhan, Fiona Campbell, Dickens Theodore

Blood (2011) 118 (21): 2232.

https://doi.org/10.1182/blood.V118.21.2232.2232

Published: 2011

Journal Articles

Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines.

Connie L. Erickson-Miller, Jennifer Kirchner, Kodandaram Pillarisetti, Lone Ottesen, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam

Blood (2009) 114 (22): 2409.

https://doi.org/10.1182/blood.V114.22.2409.2409

Published: 2009

Journal Articles

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4408.

https://doi.org/10.1182/blood.V114.22.4408.4408

Published: 2009

Journal Articles

Low or Undetectable Levels of Thrombopoietin Receptor (Tpo-R; c-mpl) Expression on Tumor Cell Lines and Primary Tumors Compared with Epo-R, ErbB2, and IGF-1R

Connie L Erickson-Miller, Antony Chadderton, Anna Gibbard, Jennifer Kirchner, Lone Ottesen, Katherine Baker, Lini Pandite, Iman El-Hariry, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam

Blood (2008) 112 (11): 5394.

https://doi.org/10.1182/blood.V112.11.5394.5394

Published: 2008

NARROW

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Chip-AML22 Master Protocol: An Open-Label Clinical Trial in Newly Diagnosed Pediatric De Novo Acute Myeloid Leukemia (AML) Patients Including a Linked Phase II Trial with Quizartinib in FLT3 -ITD/ NPM1 wt Patients - a Study By the NOPHO-DB-SHIP Consortium

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3 -Internal Tandem Duplication: Results from the Quantum-First Trial

Quantum-First Trial: FLT3 -ITD-Specific MRD Clearance Is Associated with Improved Overall Survival

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Randomized, Placebo-Controlled, Phase I/II Trial Of The Thrombopoietin Receptor Agonist Eltrombopag In Thrombocytopenic Patients With Advanced Myelodysplastic Syndromes Or Acute Myeloid Leukemia — A Subgroup Analysis Of Patients Receiving Concomitant Anticancer Therapy

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Final Results of Open-Label Treatment with Eltrombopag During ENABLE 1: A Study of Eltrombopag As An Adjunct for Antiviral Treatment of Hepatitis C Virus Associated with Thrombocytopenia

Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Low or Undetectable Levels of Thrombopoietin Receptor (Tpo-R; c-mpl) Expression on Tumor Cell Lines and Primary Tumors Compared with Epo-R, ErbB2, and IGF-1R

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only